Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases

Rahul S. Dalal, Emma McClure, Jenna Marcus, Rachel W. Winter, Matthew J. Hamilton, and Jessica R. Allegretti

Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Patients with inflammatory bowel disease (IBD) develop coronavirus disease 2019 (COVID-19) at similar rates as the general population, and there was initial concern regarding potential for severe illness.1-4 Vaccinations were authorized for emergency use in the United States in December 2020 and aim to halt the spread of COVID-19. However, there are concerns that people will be hesitant to receive the vaccine for a variety of reasons including insufficient data in certain populations including those with IBD. We surveyed patients with IBD to identify potential concerns regarding COVID-19 vaccination.

Methods

Two adult IBD populations were recruited December 22, 2020–January 26, 2021. The first included a local population of 2914 eligible patients seen at the Crohn’s and Colitis Center of Brigham and Women’s Hospital (Boston, MA). The second included a broad population identified via gastroenterology and IBD-specific social media (SM) (Supplementary Methods).

We developed an anonymous survey using the secure platform Research Electronic Data Capture (REDCap).5,6 It assessed demographics, IBD history, influenza vaccination status, and concerns and intentions regarding COVID-19 vaccination. Participants were asked if they: (1) will receive the vaccine when available; (2) will likely receive it, but at a later time; (3) are undecided; or (4) will not receive it. Those who selected options 2–4 were asked about potential reasons for vaccination hesitancy. Several methods were used to discourage multiple submissions from the same respondent and submissions from non-IBD patients (Supplementary Methods).

The primary outcome was intention to receive a COVID-19 vaccine as soon as it is available (ie, “vaccination intent”). We used multivariable logistic regression to calculate adjusted odds ratios (aORs) of factors associated with vaccination intent (Supplementary Methods). This study was approved by the institutional review board of Brigham and Women’s Hospital.

Results

A total of 906 participants (236 local, 670 SM) completed the survey. The survey response rate among local participants was 8.1%. Median age was 45 years (interquartile range, 35–62 years) for local and 40 years (interquartile range, 32–48 years) for SM participants. Self-reported influenza vaccination rates seemed to differ by population (92.0% local, 76.3% SM). Demographic and IBD characteristics are presented in Table 1.

Rates of COVID-19 vaccination intent were 80.9% for local and 60.0% for SM participants. The hesitant participants most commonly selected “concern that long-term safety of vaccines is unknown” (64.4% local, 70.1% SM) and “prefer to see how others tolerate vaccine first” (62.2% local, 55.6% SM). Approximately 70% desire data regarding vaccine safety/efficacy among patients with IBD (Supplementary Table 1).

After multivariable analysis, age ≥50 years (aOR, 2.2; 95% confidence interval [CI], 1.1–4.5) and having a bachelor’s degree (aOR, 3.3; 95% CI, 1.4–8.1) were significantly associated with vaccination intent for local participants. White race (aOR, 2.1; 95% CI, 1.2–3.9), having a bachelor’s degree (aOR, 1.7; 95% CI, 1.2–2.4), self-reported prior COVID-19 infection (aOR, 2.0; 95% CI, 1.1–3.7), and current biologic therapy (aOR, 1.5; 95% CI, 1.1–2.2) were significantly associated with vaccination intent for SM participants (Supplementary Table 2).

Discussion

A recent poll by the Kaiser Family Foundation estimates that 41% of Americans would “definitely get” the COVID-19 vaccine, although the rate among IBD patients is unknown. Our survey suggests higher vaccination intent among an IBD population, which may be caused by frequent interactions with health care providers or concerns of severe COVID-19 illness. These hypotheses...
are supported by the higher rates of influenza vaccination (92%) and COVID-19 vaccination intent (81%) among our local population, comprised entirely of referral patients. We observed that participants who are White, those age ≥50 years, those with bachelor’s degrees, those reporting prior COVID-19 infection, and those taking biologics were more likely to have vaccination intent. Those with vaccination hesitancy were largely concerned about long-term safety.

This study’s strengths include recruitment of 2 populations with distinct vaccination behaviors, a large sample, and timely distribution of surveys within 2

### Table 1. Survey Responses Pertaining to Demographics, IBD History, and COVID-19 Vaccination

| Survey items | Local (n = 236) % (fraction) | Social media (n = 670) % (fraction) |
|--------------|-------------------------------|------------------------------------|
| 1. IBD diagnosis |                               |                                    |
| Crohn’s disease | 59.8 (141/236)               | 48.4 (324/670)                    |
| Ulcerative colitis | 33.9 (80/236)               | 50.2 (336/670)                    |
| Indeterminate colitis | 6.4 (12/236)               | 1.5 (10/670)                      |
| 2. Race |                               |                                    |
| White | 96.2 (227/236) | 92.4 (619/670) |
| Black or African American | 0.9 (2/236)               | 1.6 (11/670)                      |
| Asian, Pacific Islander, or Native Hawaiian | 3.0 (7/236)               | 5.7 (38/670)                      |
| Native American or Alaska Native | 0.0 (0/236)               | 0.3 (2/670)                       |
| 3. Hispanic ethnicity | 0.4 (1/236) | 3.8 (26/670) |
| 4. Female sex | 75.4 (178/236) | 86.7 (581/670) |
| 5. Age ≥50 y | 43.2 (102/236) | 21.2 (142/670) |
| 6. IBD duration ≥10 y | 73.7 (174/236) | 52.8 (354/670) |
| 7. Level of education |                               |                                    |
| No high school degree to associate’s degree | 11.9 (28/236) | 45.6 (212/670) |
| Bachelor’s degree or master’s degree | 71.2 (168/236) | 59.6 (399/670) |
| Professional or doctorate degree | 16.9 (40/236) | 8.8 (59/670) |
| 8. Tested positive for COVID-19 at any point | 3.4 (8/236) | 6.9 (46/670) |
| 9. Current IBD medications |                               |                                    |
| Anti-TNF | 34.8 (82/236) | 45.9 (214/470) |
| Vedolizumab or natalizumab | 16.5 (39/236) | 23.3 (156/670) |
| Tofacitinib or ustekinumab | 14.8 (35/236) | 15.2 (102/670) |
| Azathioprine, 6-mercaptopurine, or methotrexate | 11.4 (27/236) | 17.8 (119/670) |
| Mesalamine | 23.3 (55/236) | 28.8 (193/670) |
| Prednisone or oral budesonide | 3.8 (9/236) | 12.5 (84/670) |
| 10. Prior exposure to 2 or more biologic therapies | 19.1 (45/236) | 24.5 (164/670) |
| 11. Prior bowel resection surgery | 34.3 (81/236) | 23.7 (159/670) |
| 12. Received or intend to receive influenza vaccine | 92.0 (217/236) | 76.3 (511/670) |
| 13. Intention to receive COVID-19 vaccine |                               |                                    |
| Yes, as soon as it is available | 80.9 (191/236) | 60.0 (402/670) |
| Not right away, but likely later in the year | 7.2 (17/236) | 14.0 (94/670) |
| Undecided | 11.0 (26/236) | 17.3 (116/670) |
| No | 0.9 (2/236) | 8.7 (58/670) |
| 14. Reasons for COVID-19 vaccination hesitancy (responses 2–4 to item #13) |                               |                                    |
| Concerned about adverse reaction to vaccine | 37.8 (17/45) | 45.5 (122/268) |
| Concerned vaccine will interfere with IBD medication efficacy | 26.7 (12/45) | 26.9 (72/268) |
| Concerned that IBD medication may render vaccine ineffective | 8.9 (4/45) | 19.8 (53/268) |
| Already had COVID-19 infection | 2.2 (1/45) | 5.6 (15/268) |
| Negative experience with last vaccine | 4.4 (2/45) | 7.8 (21/268) |
| Do not take vaccines in general | 6.7 (3/45) | 18.3 (41/268) |
| Concerned that long-term safety of vaccines is unknown | 64.4 (28/45) | 70.1 (188/268) |
| Concerned that vaccine did not undergo typical scrutiny and safety checks | 33.3 (15/45) | 41.0 (110/268) |
| Personal history of allergic reactions | 22.2 (10/45) | 18.7 (50/268) |
| Prefer to see how others tolerate vaccine first | 62.2 (28/45) | 55.6 (149/268) |

IBD, inflammatory bowel disease; TNF, tumor necrosis factor.

*Respondents could choose multiple options for survey items #9 and #14.
weeks of vaccine authorizations. Limitations include response bias inherent to online surveys. Low response rates, which are partly caused by an abbreviated study period, may overestimate vaccination intent. Therefore, our survey results do not represent the national IBD population or the full range of vaccination concerns. However, the similarity of reasons for vaccination hesitancy in 2 distinct IBD populations suggests that such concerns are commonly shared.

In summary, our study identifies a relatively high rate of COVID-19 vaccination intent among the IBD populations assessed, but concerns about long-term safety are common. Vaccination intent is associated with White race, older age, education level, prior COVID-19 infection, and current biologic therapy. Targeting outreach and educational interventions toward subpopulations less likely to have vaccination intent may facilitate COVID-19 vaccination efforts.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2021.02.004.

References

1. Brenner EJ, Ungaro RC, Geary RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020; 159:481–491.

2. Ungaro RC, Brenner EJ, Geary RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut Oct 2020. https://doi.org/10.1136/gutjnl-2020-322539.

3. Khan N, Patel D, Xie D, et al. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? Results from a nationwide Veterans’ Affairs cohort study. Am J Gastroenterol Oct 2020. https://doi.org/10.14309/ajg.0000000000001012.

4. Derikx LAAP, Lantinga MA, de Jong DJ, et al. Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis Oct 2020. https://doi.org/10.1093/ecco-jcc/jjaa215.

5. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.

6. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.

7. KFF COVID-19 Vaccine Monitor: December 2020. Kaiser Family Foundation; 2020. Available at: https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/. Accessed January 4, 2021.

Reprint requests
Address requests for reprints to: Jessica R. Allegretti, MD, MPH, 850 Boylston Street, Suite 201, Chestnut Hill, Massachusetts 02467. e-mail: jallegretti@bwh.harvard.edu; fax: (617) 732-9198.

Conflicts of interest
These authors disclose the following: Matthew J. Hamilton serves as a consultant for Pfizer and Takeda; and has grant support from AbbVie and Takeda. Jessica R. Allegretti serves as a consultant for Takeda, Janssen, Pfizer, Pandion, Sercatus, Finch Therapeutics, Iterative Scopes, and Artugen; and has grant support from Merck. The other authors disclose no conflicts.

Funding
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (ST32DK007533 to R.S.D.).
Supplementary Methods

Recruitment

The local population was sent survey links directly via email. This included 2914 patients receiving care at the Crohn’s and Colitis Center of Brigham and Women’s Hospital (Boston, MA) with a documented email address and diagnosis code for Crohn’s disease (ICD-10-CM K50), ulcerative colitis (ICD-10-CM K51), or indeterminate colitis (ICD-10-CM K52.3) obtained from the electronic medical record. The social media population (among the general public) was recruited via postings of a separate survey link on our gastroenterology division’s Twitter page and on IBD-focused Facebook groups. Facebook groups were identified using the search terms “inflammatory bowel disease,” “IBD,” “Crohn,” and “ulcerative colitis.” Facebook groups specific to countries outside of the United States and groups with fewer than 1000 members were not included. A total of 17 Facebook groups met this search criteria. Although the total number of Facebook group members exceeds 20,000, the precise number of eligible patients with IBD from both Twitter and Facebook groups cannot be determined.

All respondents were assigned a unique identification number; however, Internet Protocol addresses could not be tracked to prevent respondents from completing the survey more than once. Therefore, the text “Please only complete this survey once” was included in bold immediately before the first survey question to discourage multiple submissions from the same respondent. Additionally, all survey submissions were manually reviewed and no 2 submissions had identical responses to all survey items. To discourage responses from non-IBD patients, all survey invitations and instructions in the survey header indicate that the survey is intended for patients with IBD. Additionally, all survey items, 7 of which include specific questions about IBD history, require a response for successful submission. Therefore responses from non-IBD patients would require intentional fabrication. Respondents were not provided reimbursement or other incentivization for completing the survey. The survey instrument was tested for proper functionality before publishing online.

Statistical Analysis: Regression

We used univariable logistic regression to calculate unadjusted odds ratios of factors associated with vaccination intent for each study population. Factors with $P < .10$ on univariable analysis were included in multivariable analyses. Factors with $P < .05$ on multivariable analysis were considered significant. Statistical analyses were performed using Stata/IC version 15.1 (StataCorp, College Station, TX).

Supplementary Table 1. Additional Survey Responses Specific to COVID-19 Vaccination

| Survey items                                                                 | Local (n = 236) | Social media (n = 670) |
|------------------------------------------------------------------------------|----------------|-----------------------|
| 15. COVID-19 vaccine will be important for health of others                   | 96.2 (227/236) | 90.9 (609/670)        |
| 16. COVID-19 vaccine will be important for my health                         | 95.8 (226/236) | 83.6 (560/670)        |
| 17. Someone close to me was negatively affected by COVID-19                  | 48.7 (115/236) | 46.3 (310/670)        |
| 18. My IBD provider’s recommendation is an important factor in my decision to take the COVID-19 vaccine | 92.0 (217/236) | 80.6 (540/670)        |
| 19. What can IBD providers do to better inform you about the COVID-19 vaccines?* |                |                       |
| Have a conversation with me about risks/benefits                             | 58.9 (139/236) | 67.5 (452/670)        |
| Provide me an informational handout                                         | 31.4 (74/236)  | 32.8 (220/670)        |
| Provide me data about vaccine safety/efficacy among patients with IBD or other autoimmune disorders | 66.5 (157/236) | 71.3 (478/670)        |
| Provide me data about vaccine safety/efficacy among patients with IBD who take my medication(s) | 67.4 (159/236) | 71.5 (479/670)        |
| Nothing                                                                      | 9.3 (22/236)   | 10.0 (67/670)         |

IBD, inflammatory bowel disease.

*Respondents could choose multiple options for survey item #19.
### Supplementary Table 2. Logistic Regression of Factors Associated With Intention to Receive COVID-19 Vaccine

| Predictor                              | Local survey (n = 236) | Social media survey (n = 670) |
|----------------------------------------|------------------------|-------------------------------|
|                                        | **Univariable OR (95% CI)** | **Multivariable OR (95% CI)** | **Univariable OR (95% CI)** | **Multivariable OR (95% CI)** |
| Crohn’s disease                        | 0.78 (0.40–1.54)       | 1.52 (1.11–2.07)              | 1.38 (1.00–1.92)            |
| White race                             | 1.22 (0.25–6.09)       | 2.10 (1.18–3.73)              | 2.13 (1.17–3.85)            |
| Hispanic ethnicity                     | —                      | 0.56 (0.25–1.23)              | —                            |
| Female sex                             | 0.85 (0.39–1.84)       | 0.87 (0.55–1.38)              | —                            |
| Age ≥50 y                              | 1.89 (0.95–3.78)<sup>a</sup> | 2.21 (1.07–4.54)<sup>b</sup> | 1.27 (0.93–1.73)            |
| IBD duration ≥10 y                     | 1.03 (0.49–2.14)       | 1.30 (0.93–1.83)              | —                            |
| Bachelor’s or more advanced degree     | 2.75 (1.17–6.45)<sup>a</sup> | 3.31 (1.36–8.06)<sup>b</sup> | 1.63 (1.17–2.27)<sup>a</sup> | 1.72 (1.22–2.41)<sup>b</sup> |
| Had COVID-19 infection                 | 1.43 (0.28–7.35)       | 1.87 (1.02–3.41)<sup>a</sup> | 2.02 (1.09–3.73)<sup>b</sup> |
| Prior IBD bowel resection              | 1.06 (0.53–2.10)       | 1.35 (0.93–1.96)              | —                            |
| Current biologic                       | 0.93 (0.47–1.84)       | 1.67 (1.19–2.33)<sup>a</sup> | 1.52 (1.07–2.16)<sup>b</sup> |
| Current thiopurine or methotrexate     | 1.40 (0.46–4.28)       | 1.27 (0.84–1.93)              | —                            |
| Current corticosteroids                | 1.92 (0.23–15.78)      | 1.03 (0.65–1.65)              | —                            |
| ≥2 prior biologic exposures            | 1.11 (0.47–2.58)       | 1.39 (0.96–2.01)<sup>a</sup> | 1.16 (0.79–1.71)            |

**NOTE.** Missing univariable values for Hispanic ethnicity are caused by an insufficient number of observations in the local survey. CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio.

<sup>a</sup><sup>P < .10</sup> on univariable analysis. Only these variables were candidates for multivariable analysis.

<sup>b</sup><sup>P < .05</sup> on multivariable analysis.